论文部分内容阅读
二甲双胍(metformin)于1957年上市,经大量临床和实验研究证实,治疗2型糖尿病T2DM安全、有效。目前美国糖尿病学会(ADA)/欧洲糖尿病研究会(EASD)以及中国等多个国家指南中,二甲双胍作为T2DM一线药物的地位获得了进一步的确定与巩固。近年随着对其降糖及降糖外作用的研究不断深入,临床应用范围不断拓宽,已显示出二甲双胍不仅能有效地降低血糖,还能防治其他疾病。现将其临床应用和研究进展作一简要综述。
Metformin (metformin) was listed in 1957, after a large number of clinical and experimental studies confirmed that T2DM treatment of type 2 diabetes is safe and effective. Currently, the status of metformin as a first-line T2DM drug is further confirmed and consolidated in several national guidelines such as the American Diabetes Association (ADA) / European Diabetes Association (EASD) and China. In recent years, with its hypoglycemic and hypoglycemic effect of the research continues to deepen, the clinical application of continuous broadening, has shown that metformin can not only effectively reduce blood sugar, but also prevent other diseases. Now a brief overview of its clinical application and research progress.